Pharmaceutical Research & Drug Development – Page 12

Prototype not scalable during early development – regulatory expectations for formulation data

Recognizing symptoms early on can prevent further complications. In the context of formulation development, certain signals may suggest that a prototype is not scalable:Click to read the full article.

Prototype not scalable during early development – regulatory expectations for formulation data

Recognizing symptoms early is essential to mitigate potential risks associated with non-scalable prototypes. Key indicators include:Click to read the full article.

Bioavailability risk flagged during tech transfer – CMC risk assessment and mitigation

Recognizing the symptoms of bioavailability risks during tech transfer is crucial for timely intervention. Common signals include:Click to read the full article.

Excipient incompatibility identified late during IND/NDA filing – CMC risk assessment and mitigation

Detecting early indicators of excipient incompatibility is critical for mitigating potential issues. The following symptoms may arise during the formulation or processing stages:Click to read the full article.

Excipient incompatibility identified late during tech transfer – preventing late-stage reformulation

Identifying symptoms early in the process helps prevent further complications. Symptoms related to excipient incompatibility can manifest in various ways, including:Click to read the full article.

Formulation fails stability targets during tech transfer – regulatory expectations for formulation data

Identifying early symptoms and signals of stability failures is critical. Symptoms may manifest variably depending on the formulation and process conditions. Common indicators include:Click to read the full article.

Prototype not scalable during early development – how to redesign formulation strategy

Strategies for Redesigning Formulation to Address Scalability Issues in Early Development In pharmaceutical research and drug development, early-stage formulators often encounter the challenge of prototypes that are not scalable. This…

Formulation fails stability targets during tech transfer – preventing late-stage reformulation

Strategies to Address Stability Failures During Tech Transfer in Formulation Development Formulation development is a critical phase in drug manufacturing, particularly during tech transfer when production processes scale up. Failing…

Bioavailability risk flagged during tech transfer – preventing late-stage reformulation

Managing Bioavailability Risks During Technology Transfer: An Actionable Playbook In the highly regulated world of pharmaceutical manufacturing, one significant concern that can surface during the technology transfer phase is the…

Dissolution variability unexplained during early development – how to redesign formulation strategy

Recognizing the signs of dissolution variability early in pharmaceutical development is critical for swift remediation. Symptoms may manifest in various ways during the analytical and manufacturing processes, including:Click to read…

Dissolution variability unexplained during early development – preventing late-stage reformulation

Addressing Unexplained Dissolution Variability During Early Development to Avoid Late-Stage Reformulation Dissolution variability during early development phases can pose significant challenges in formulation development. It can lead to delayed timelines,…

QbD elements missing during scale-up preparation – regulatory expectations for formulation data

Identifying early warning signals is crucial for addressing QbD gaps. Symptoms may be evident on the manufacturing floor or in laboratory settings. Look for the following indicators:Click to read the…